{
  "abstract": "Antigen heterogeneity and antigen-negative relapse represent major limitations to durable CAR-T cell efficacy in B-lineage malignancies. We previously developed the Adapter CAR-T cell (AdCAR-T) platform, which enables flexible redirection of engineered T cells to distinct surface antigens through biotinylated adapter molecules (AMs). In this study, AMs generated from an in-house-produced tafasitamab biosimilar (anti-CD19), commercial rituximab (anti-CD20), and an in-house-produced daratumumab biosimilar (anti-CD38) mediated potent, antigen-specific AdCAR-T cell cytotoxicity. While single-antigen targeting resulted in the selection of antigen-negative tumor populations, simultaneous targeting of CD19, CD20, and CD38 effectively controlled a defined heterogeneous Burkitt lymphoma model in vitro and induced sustained tumor control in vivo. Selective loss of the CD38+ AdCAR-T cell population after CD38-directed AM exposure was consistent with fratricide; however, the surviving CD38low population retained cytotoxic activity. These findings establish combinatorial AdCAR-T cell targeting as a flexible pan-B-lineage strategy for addressing pre-existing antigen heterogeneity and support further development of antibody-derived AM combinations for B-cell malignancies.",
  "abstract_shown": true,
  "affiliations": [
    "Hopp Children's Cancer Center Heidelberg (KiTZ)"
  ],
  "article_type": "New results",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "name": "S. Krost"
    },
    {
      "name": "A.-S. Mast"
    },
    {
      "name": "D. Atar"
    },
    {
      "name": "B. Kristmann"
    },
    {
      "name": "S. Scheuermann"
    },
    {
      "affs": [
        0
      ],
      "name": "C. M. Seitz"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/by4f828a0enj3.bib",
  "cited_by": 0,
  "doi": "10.64898/2026.09.12.751171",
  "fulltext_url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751171v1.full",
  "id": "by4f828a0enj3",
  "issns": [],
  "landing_url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751171v1",
  "language": null,
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "biorxiv",
      "immunology"
    ],
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7213588339",
  "pdf_url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751171v1.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-12",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/by4f828a0enj3.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:23:09Z",
      "native_id": "10.64898/2026.09.12.751171",
      "source": "biorxiv",
      "url": "https://www.biorxiv.org/content/10.64898/2026.09.12.751171v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "biorxiv:immunology",
      "subfield": "immunology"
    }
  ],
  "title": "Pan-B-Lineage Targeting with Adapter CAR-T Cells Controls Antigen-Heterogeneous Lymphoma",
  "title_text": "Pan-B-Lineage Targeting with Adapter CAR-T Cells Controls Antigen-Heterogeneous Lymphoma",
  "type": "preprint",
  "updated_at": "2026-10-30T12:23:09Z",
  "url": "https://research.draconitic.com/paper/by4f828a0enj3",
  "venue": "bioRxiv",
  "versions": []
}